TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03130725

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amalgam sealant
Description: Amalgam sealant placed on incipient enamel caries and deep enamel fissures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resin based sealant
Description: Resin based sealant placed on incipient enamel caries and deep enamel fissures.
Study: NCT05439343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain scores (numerical rating scale at rest and motion)
Description: As the primary outcome of the present clinical study, pain scores will be assessed with numerical rating scale at both rest and motion on both knees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain scores (numerical rating scale at rest and motion)
Description: As the primary outcome of the present clinical study, pain scores will be assessed with numerical rating scale at both rest and motion on both knees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Description: Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale will be used as the questionnaires for functional assessment. Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of knee joints.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Description: Brief Pain Inventory (Short Form), WOMAC Osteoarthritis index, and Lower extremity functional scale will be used as the questionnaires for functional assessment. Rehabilitation physiotherapy will be assessed with knee range of motion (both active and maximal passive), muscle power at abduction and adduction, single leg stance test, six-minute walk test for assessment of the functional recovery of knee joints.
Study: NCT04048889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Continuous femoral nerve block with injection of 15 mls of Ropivacain 0.5% adjacent to the lateral aspect of the femoral nerve below the fascia iliaca and placement of the catheter within the vicinity of the femoral nerve, juste deep to the fascia iliaca.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Popliteal plexus block with injection of 15 mls of Ropivacain 0.5% inside the distal end of the adductor canal close to the adductor hiatus, adjacent to the femoral artery, between the medial vastus muscle and the adductor Magnus muscle, done under general anesthesia.
Study: NCT02517086

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic exercises
Description: The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: elastic compression
Description: exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
Study: NCT00399607

Intervention type: PROCEDURE
Intervention: Rectal biopsy during colonoscopy
Description: Biopsies of rectal tissue will be obtained during the 3 or 5 year follow-up colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.

Intervention type: PROCEDURE
Intervention: Rectal biopsy at randomization
Description: Biopsies of rectal tissue will be obtained at the time of randomization. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.

Intervention type: PROCEDURE
Intervention: Rectal biopsy at 1 year
Description: Biopsies of rectal tissue will be obtained at the time of the one year follow-up visit. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.

Intervention type: PROCEDURE
Intervention: Rectal biopsy prior to colonoscopy
Description: Biopsies of rectal tissue will be obtained 7-21 days prior to the 3 or 5 year colonoscopy. The collection of rectal biopsies involves inserting a tube-about as long and big around as a doctor's examining finger-through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk-about like having blood drawn.

Intervention type: PROCEDURE
Intervention: Biopsies during colonoscopy
Description: Biopsies of the rectum, sigmoid colon and ascending colon will be obtained during the 3-5 year follow-up colonoscopy. The colonoscopy involves insertion of a flexible tube through the anus, which is then advanced the full length of the colon. Biopsies (tiny pinches of tissue less than 1/16 of an inch thick) will be taken as the colonoscopy tube is being removed. In total, 12-16 biopsies will be taken from the rectum (or lower colon about 3 - 4 inches up), sigmoid colon and ascending colon.
Study: NCT02120352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
Study: NCT02870062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily baths with chlorhexidine wipes, oral spray and standard shampoo
Description: Description already mentioned in arm/group descriptions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Daily baths with placebo wipes, oral spray and shampoo
Description: Description already mentioned in arm/group descriptions.
Study: NCT03074201

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cholangioscopy
Description: Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
Study: NCT02120352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/3TC Oral tablets
Description: ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABC/3TC Oral tablets
Description: ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPV Oral Tablets
Description: Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RPV Oral Tablets
Description: Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104

Intervention type: OTHER
Group type: OTHER
Intervention: HAART
Description: Higly-active antiretroviral therapy chosen by participant based on investigator recommendations and based on availability.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV
Description: Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV
Description: Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV
Description: Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPV
Description: Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
Study: NCT03007719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Ara-G
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorine F 18 Ara-G
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MR imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MR imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MR imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MR imaging
Study: NCT02517086

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functional compressive bandaging
Description: exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
Study: NCT02461628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Malaria RDT & conditional voucher for ACT from retail sector
Description: Trained community health volunteers will offer eligible household members free malaria rapid diagnostic tests and a voucher allowing the purchase of a qualified ACT at a reduced fixed price in the retail sector conditional on a positive test
Study: NCT01497704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YN968D1
Description: Daily dosing of YN968D1 for treatment of solid tumors
Study: NCT02088372

Intervention type: DEVICE
Intervention: Vanguard with E1 PS Bearing
Description: Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population
Study: NCT04910698

Intervention type: DRUG
Intervention: Antibiotic
Description: Antibiotic duration of treatment defined if the patient belonged to long course or short course group.
Study: NCT04190810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhibition
Description: Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Classical AAT
Description: Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Participants receive an Ipad, on which the app is installed. They are instructed to train for a period of three weeks for at least 15 minutes a day.
Study: NCT02064114

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group
Description: Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Followed for a period of 3,6 and 12 months after the procedure.
Study: NCT04418843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Endoscopic Mucosal Resection
Description: Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp with electrocautery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold Snare Endoscopic Mucosal Resection
Description: Use of injected colloidal or saline solution to raise a lesion prior to polypectomy snare closed over a polyp without electrocautery
Study: NCT00925080

Intervention type: DEVICE
Intervention: IVBG
Description: Venous blood glucose measurement every 7.5 minutes for 72-hours
Study: NCT00991224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT-gag-TCR modified T cells
Description: Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT-gag-TCR modified T cells
Description: Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: α/6-gag-TCR modified T cells
Description: Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: α/6-gag-TCR modified T cells
Description: Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STI or Drug Holiday
Description: Subjects will stop taking antiviral medications for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STI or Drug Holiday
Description: Subjects will stop taking antiviral medications for 16 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STI or Drug Holiday
Description: Subjects will stop taking antiviral medications for 16 weeks.
Study: NCT03074201

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spyglass DS Cholangioscope
Description: Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
Study: NCT04060004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling is a technique used by physiotherapists.
Study: NCT00991224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: STI or Drug Holiday
Description: Subjects will stop taking antiviral medications for 16 weeks.
Study: NCT04060004

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham dry needling
Description: Sham dry needling is a technique used by physiotherapists to compare the effects of dry needling.

Intervention type: OTHER
Group type: OTHER
Intervention: Electrotherapy + therapeutic exercise
Description: Standard care of neck pain.
Study: NCT03914534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid 500 MG
Description: Administration of 500 mg of Valproic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valcote 500 mg
Description: Administration of 500 mg of Valproic Acid
Study: NCT01711658

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: Intensity modulated radiation therapy (IMRT), 35 fractions over 6 weeks, 6 fractions per week for 5 weeks and 5 fractions per week for 1 week, 2 Gy per fraction to total dose of 70 Gy

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: IMRT
Description: Intensity modulated radiation therapy (IMRT), 35 fractions over 6 weeks, 6 fractions per week for 5 weeks and 5 fractions per week for 1 week, 2 Gy per fraction to total dose of 70 Gy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m\^2 administered intravenously on days 8 and 29

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m\^2 administered intravenously on days 8 and 29

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1500 mg placebo daily by mouth or by feeding tube starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: 1500 mg lapatinib by mouth or by feeding tube daily starting 7 days before IMRT for 7 weeks prior to and during IMRT and 3 months after completion of IMRT
Study: NCT02527187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 HEP/mL Betula verrucosa allergen extract
Description: The investigational product contained 10 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 HEP/mL Betula verrucosa allergen extract
Description: The investigational product contained 10 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25 HEP/mL Betula verrucosa allergen extract
Description: The investigational product contained 25 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25 HEP/mL Betula verrucosa allergen extract
Description: The investigational product contained 25 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 HEP/mL Betula verrucosa allergen extract
Description: The investigational product contained 50 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 HEP/mL Betula verrucosa allergen extract
Description: The investigational product contained 50 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 HEP/mL Betula verrucosa allergen extract
Description: The investigational product contained 100 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 HEP/mL Betula verrucosa allergen extract
Description: The investigational product contained 100 HEP/mL Betula verrucosa allergen extract and was tested by administration onto skin. The test was carried out on the forearm following prick test technique.
Study: NCT01764672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral intake of 2 placebo tablets
Study: NCT04789135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Treatment consists of direct instillation into the bladder of ozone gas, with concentration of 20µg / ml - 60ml via urethral catheter.